Abbott

ABT

Market cap $176B

Abbott Laboratories (NYSE: ABT) will release earnings for its first quarter before the opening bell on Thursday, April 16.

Besides Wall Street's top-and-bottom-line estimates for Abbott (ABT), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2026.

A jury in Chicago on Thursday said Abbott Laboratories must pay $53 million in compensatory damages to a group of families that had accused the company of failing to warn that its formula for premature infants can cause a potentially deadly bowel disease, according to the Chicago Tribune.

Abbott (ABT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

With chronic disease on the rise, a new survey from Abbott shows information overload, confusion and cost leave many Americans struggling, worrying about how to stay healthy ABBOTT PARK, Ill., April 9, 2026 /PRNewswire/ -- Today, Abbott (NYSE: ABT), a global leader in chronic disease prevention, treatment and care, is releasing new survey findings highlighting a growing tension: 74% of U.S. adults believe most chronic diseases, such as diabetes or cardiovascular disease, are preventable, but only 1 in 4 feel very confident in knowing how to care for their health.

Abbott Laboratories has declined over 16% since my last review, which was previously rated a HOLD, as the valuation was a little rich. The acquisition of Exact Sciences adds a solid piece to a company with a long, proven track record. The segments were kind of a mixed bag in the most recent earnings report, and I'll be monitoring the struggling areas to see where they might go.

In the closing of the recent trading day, Abbott (ABT) stood at $103.56, denoting a +1.7% move from the preceding trading day.

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

In the world of investing, stability is a prized commodity. Few companies embody that stability better than Abbott Laboratories NYSE: ABT, a diversified healthcare powerhouse and a member of the elite dividend kings.

During a year when other healthcare stocks from the S&P500 have remained roughly flat, Abbott Laboratories (ABT) has struggled and lost ground by 22%. ABT which will announce Q1 earnings on the 16th of April is facing low revenue expectations for the quarter, but double-digit growth is expected in the following quarters. I highlight how ABT's financial profile and FCF base is solid enough to support continued annual dividend hikes where the yield is now at-year highs.